Imafix 100 Capsule contains Imatinib Mesylate 100mg, a selective tyrosine kinase inhibitor widely used in targeted cancer therapy for chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies. It effectively inhibits abnormal cell proliferation by targeting BCR-ABL and related proteins.
This capsule formulation provides consistent bioavailability and reliable therapeutic effects, making it suitable for outpatient and inpatient oncology treatment protocols. It allows for precise dosing and long-term administration as recommended by oncologists.
For distributors and hospital suppliers, Imafix 100 Capsule is a high-demand oncology product, routinely required in cancer treatment centers, specialty hematology clinics, hospital oncology wards, and institutional pharmacies. Its steady prescription pattern ensures continuous demand.
Adding Imafix 100 Capsule enhances your oncology and targeted therapy segment, providing opportunities in hospital supply chains, retail pharmacy distribution, bulk institutional orders, export markets, and third-party manufacturing. Its clinical importance and ongoing demand make it a highly profitable addition for pharmaceutical distributors.